VYTRUS BIOTECH EO -01 (V5P) - Total Assets
Based on the latest financial reports, VYTRUS BIOTECH EO -01 (V5P) holds total assets worth €14.66 Million EUR (≈ $17.14 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can VYTRUS BIOTECH EO -01 service its debt to assess how comfortably operating cash covers total debt obligations.
VYTRUS BIOTECH EO -01 - Total Assets Trend (2021–2025)
This chart illustrates how VYTRUS BIOTECH EO -01's total assets have evolved over time, based on quarterly financial data. See what is VYTRUS BIOTECH EO -01's book value for net asset value and shareholders' equity analysis.
VYTRUS BIOTECH EO -01 - Asset Composition Analysis
Current Asset Composition (December 2025)
VYTRUS BIOTECH EO -01's total assets of €14.66 Million consist of 36.8% current assets and 63.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 23.0% |
| Accounts Receivable | €982.01K | 6.7% |
| Inventory | €623.02K | 4.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.96 Million | 33.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how VYTRUS BIOTECH EO -01's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of VYTRUS BIOTECH EO -01.
Key Asset Composition Facts
- Current vs. Non-Current Assets: VYTRUS BIOTECH EO -01's current assets represent 36.8% of total assets in 2025, an increase from 25.3% in 2021.
- Cash Position: Cash and equivalents constituted 23.0% of total assets in 2025, up from 17.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, a decrease from 39.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 33.8% of total assets.
VYTRUS BIOTECH EO -01 Competitors by Total Assets
Key competitors of VYTRUS BIOTECH EO -01 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
VYTRUS BIOTECH EO -01 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.03 | 3.03 | 3.28 |
| Quick Ratio | 2.68 | 2.61 | 2.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.61 Million | €2.54 Million | €2.46 Million |
VYTRUS BIOTECH EO -01 - Advanced Valuation Insights
This section examines the relationship between VYTRUS BIOTECH EO -01's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 13.20 |
| Latest Market Cap to Assets Ratio | 8.97 |
| Asset Growth Rate (YoY) | 31.7% |
| Total Assets | €14.66 Million |
| Market Capitalization | $131.54 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values VYTRUS BIOTECH EO -01's assets at a significant premium (8.97x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: VYTRUS BIOTECH EO -01's assets grew by 31.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for VYTRUS BIOTECH EO -01 (2021–2025)
The table below shows the annual total assets of VYTRUS BIOTECH EO -01 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €14.66 Million ≈ $17.14 Million |
+31.72% |
| 2024-12-31 | €11.13 Million ≈ $13.01 Million |
+19.50% |
| 2023-12-31 | €9.31 Million ≈ $10.89 Million |
+16.38% |
| 2022-12-31 | €8.00 Million ≈ $9.36 Million |
+11.43% |
| 2021-12-31 | €7.18 Million ≈ $8.40 Million |
-- |
About VYTRUS BIOTECH EO -01
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more